Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Description du projet

Identifier la cause des réponses négatives des patients au traitement

L’identification des mécanismes moléculaires qui influencent de manière positive ou négative la réponse d’un patient au traitement médical est une question essentielle parmi les professionnels de la santé. Une étude promue par 3TR, un consortium d’institutions universitaires, de PME et d’entreprises pharmaceutiques de premier plan, se penchera sur cette question. Le projet financé par l’UE appliquera des méthodes bio-informatiques et de contrôle pour recueillir et analyser des données issues d’échantillons de sang, de tissus et d’autres liquides pendant toute la durée du traitement. Il créera une plateforme centralisée des données pour améliorer la gestion et établira un tableau clinique et moléculaire inclusif présentant des patients atteints de maladies similaires. Le projet entend expliquer le rôle joué par notre microbiome, notre génétique et notre génomique régulatrice pendant le traitement.

Objectif

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Coordinateur

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.
Contribution nette de l'UE
€ 9 468 779,68
Adresse
AVENIDA AMERICO VESPUCIO 15 EDIF S2
41092 Sevilla
Espagne

Voir sur la carte

Région
Sur Andalucía Sevilla
Type d’activité
Research Organisations
Liens
Coût total
€ 9 579 779,68

Participants (85)